On this site you will find clinical studies with cannabis or single
cannabinoids in different diseases and case reports on the use of cannabis by
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.
|Title||[Randomized comparative trial of a new anti-emetic: nabilone, in cancer patients treated with cisplatin][Article in French]|
|Author(s)||George M, Pejovic MH, Thuaire M, Kramar A, Wolff JP.|
|Journal, Volume, Issue||Biomed Pharmacother. 1983;37(1):24-7.|
|Major outcome(s)||Nabilone, in comparison with chlorpromazine did not significantly reduce the number of vomiting, but most patients preferred nabilone.|
A randomized, double-blind controlled trial of nabilone versus chlorpromazine was performed in 20 patients with advanced gynaecological cancer who received chemotherapy including cis-platinum. Each patient served as his own control. Nabilone was administered at a dose of 3 mg given orally three times a day, starting the day before cis-platinum and ending the day after. Chlorpromazine was administered at a dose of 12.5 mg given IM, 15 minutes before the start of cis-platinum. Nabilone, in comparison with chlorpromazine did not significantly reduce the number of vomiting. Ten patients preferred nabilone, 5 preferred chlorpromazine and 3 were undecided. Predominant side effects noted by patients were similar for both agents and included somnolence, dry mouth and orthostatic hypotension. No other intervention besides reassurance of the patient was necessary to treat these adverse reactions.
|Duration (days)||3 mg three times a day|
|Participants||20 patients with advanced gynaecological cancer who received|
|Type of publication||Medical journal|
|Address of author(s)|